J&J’s Rybrevant/Lazcluze MARIPOSA Update Shows Greater Gains Over Tagrisso

Subcutaneous Rybrevant Data Reinforce Safety, Convenience

 
• By Mandy Jackson
  
3d rendered, medically accurate illustration of lung cancer. showing presence of cancerous tumor inside the lungs
Rybrevant plus Lazcluze efficacy continued to separate from Tagrisso monotherapy • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D